Ligation based endoscopic platform

Revolutionizing endoscopic treatment

Empowering endoscopists to transform lives through innovative, minimally invasive solutions for GERD, obesity and diabetes.

Get updates →See the platform

2024Founded

15Countries

<30Minute procedure

0Incisions

WindowLock™ band Applied endoscopically

GERDObesityType 2 DiabetesARBMEBGDMRWindowLock™ bandLigation basedOutpatientNo incisionsGERDObesityType 2 DiabetesARBMEBGDMRWindowLock™ bandLigation basedOutpatientNo incisions

The platform

1 platform. 3 metabolic conditions.

EndoBand utilizes Endolastic™ technology to deliver versatile and precise support for tissue management, empowering professionals with a minimally invasive, reliable solution.

ARBMPending FDA approval

GERD

Anti-Reflux Band Mucosectomy

Our Endolastic™ technology provides a minimally invasive solution for chronic acid reflux, offering long-term relief without the need for ongoing medication.

EBGPending FDA approval

Obesity

Endoscopic Band Gastroplasty

Endolastic's innovative approach helps patients achieve sustainable weight loss through a quick, outpatient procedure with minimal recovery time.

DMRPending FDA approval

Type 2 Diabetes

Duodenal Mucosal Resurfacing

By addressing obesity, our technology aids in managing type 2 diabetes, potentially reducing medication dependence and improving overall health outcomes.

Why Endolastic

The Endolastic™ difference

Minimally invasive ligation based procedure
MAC sedation enables ASC patient access
Treats the source, not the symptom
Targets dysfunctional GI tissue
Quick recovery time
Customizable for various applications
Natural tissue regeneration
Repeatable and adjustable

Procedure

How the Endolastic platform works

1
Minimally invasive
Endolastic's WindowLock™ bands are applied endoscopically. No incisions are needed.
- Reduced risk of infection and complications
- Can be performed in an outpatient setting
2
Quick procedure
Endolastic procedures typically take less than 30 minutes, with minimal recovery time.
- Faster recovery than surgical procedures
- Conscious sedation reduces the need for general anesthesia
3
Effective results
Patients experience significant improvement in symptoms, often within days of the procedure.
- Ligation based pressure zones stimulate the body's natural healing
- The procedure can be safely repeated if necessary

Band applied through the scope

Pseudo polyp cross section

WindowLock™ band

About

Leadership and advisors

Founded in 2024, Endolastic emerged from a vision to transform the landscape of minimally invasive treatments. Our solutions are making a difference in patients' lives across 15 countries.

Fritz Haller

Co-founder & CEO

With over 20 years of experience in medical device innovation, Fritz leads Endolastic's strategic vision and operations.

Paul Robertson

Co-founder & CPO

Paul brings extensive expertise in biomedical engineering, driving Endolastic's technological advancements and R&D efforts.

Dr. Mohamed Abeid

Consultant Gastroenterologist and Bariatric Endoscopist · Advisor

Over 20 years of experience and more than 50,000 upper endoscopies performed. A pioneering force in minimally invasive endoscopic treatments for obesity and GERD.

Dr. Jose M. Nieto

Advanced Therapeutic Endoscopist · Advisor

Pioneer of the Antireflux Band Mucosectomy (ARBM) technique, demonstrating the power of band ligation technology in treating refractory GERD.

For distributors

Join our network

We are actively assessing strategic partnership opportunities with a select group of distributors, as part of our comprehensive global go-to-market strategy, encompassing both direct and distribution-led channels.

High-demand, innovative products
Significant market potential in GERD, obesity, and diabetes
Cost-effective solutions with high margins
Easy to demonstrate and train physicians
Complements existing endoscopic product lines
Potential for recurring revenue through disposable components